BioSight Ltd, a pharmaceutical company developing innovative therapeutics for hematological malignancies and disorders, announced today that the FDA has granted Fast Track designation for BST-236 for the treatment of acute myeloid leukemia (AML).
Biosight Granted U.S. FDA Fast Track Designation for BST-236 for the Treatment of Acute Myeloid Leukemia
